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constituents and antiosteoporotic efficacy.
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Different Epimedium for osteoporosis prevention 15of bone tissue, and biological activity between XEP and XEK using an established ovariecto-
mised (OVX) rat model.
Results: Six flavonoids with different contents between XEK and XEP were identified. As
compared with the OVX group, significantly higher bone mineral density, elastic-modulus,
and compressive strength were found in both the XEK group and XEP group (p < 0.05 for all,
n Z 8). Histomorphometric data presented significantly higher osteoblast surface ratio and
osteoid area accompanied by significantly lower values of erosion surface and adiopocytes area
in two treatment groups (p < 0.05, nZ 6). XLGB Fufang with either XEK or XEP all showed sig-
nificant preventive effects in OVX-induced osteoporosis and deterioration of bone mechanical
properties.
Conclusion: The significance of the current preclinical experimental study was that these two
Epimedium species used for formulating XLGB capsules were equally effective for the preven-
tion of oestrogen-depletion induced osteoporosis.
Copyright ª 2015, The Authors. Published by Elsevier (Singapore) Pte Ltd. This is an open ac-
cess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Introduction
Osteoporosis and osteoporotic fractures occur at metaboli-
cally more active and faster deteriorating trabecular regions
such as at the spine and hip [1,2]. Prevention and treatment
of osteoporosis is essential in avoiding osteoporotic frac-
tures, especially in postmenopausal women. Hormone (oes-
trogen) replacement therapy is one of the first-line effective
countermeasures for relievingmenopausal symptoms and for
the prevention and treatment of postmenopausal bone loss
[3]. However, the Women’s Health Initiative trial data
caused concerns being raised both in postmenopausal
women and their physicians due to the increased risk of
breast cancer and cardiovascular events [4].
Herbal Fufang or formula is a popular alternative in
traditional Chinese Medicine (TCM) developed for the pre-
vention and treatment of osteoporosis and related bone
metabolic diseases [5,6]. Xian Ling Gu Bao Fufang (XLGB)
was developed based on the modification of the empirical
“Miao minority” medicine, which was traditionally used to
tone the “kidney system” and nourish bones in oriental
herbal medicine [7]. XLGB capsule was officially approved
by the Chinese State Food and Drug Administration and was
served as an over-the-counter drug for the treatment of
osteoporosis, osteoarthritis, aseptic osteonecrosis, and
fractures [5]. As a phytoestrogen-rich TCM [8], preclinical
studies showed that XLGB improved bone mineral density
(BMD) and mechanical properties in ovariectomised (OVX)
rat models [9]. Clinical data demonstrated its positive ef-
fects in promoting fracture healing [10] and in the treat-
ment of osteoporosis [10]. Recently, a multicentre, double
blind, placebo-controlled, and dose-effect clinical trial
further confirmed the safety and efficacy of XLGB in post-
menopausal women with osteoporosis [5].
As a herbal Fufang, XLGB consists of six herbs with
different percentages in weight as follows: Herba Epimedii
folium (70%), Dipsaci Radix (10%), Salvia Miltiorrhizae Radix
et Rhizoma (5%), Anemarrahenae Rhizoma (5%), Psoraleae
Fructus (5%), and Rehmannia Radix (5%) [5]. Undoubtedly, as
the “monarch” herb in XLGB Fufang based on TCM theory, the
source of Herba Epimedii is of great importance for its long-term sustainable development. In Chinese Pharmacopoeia
before 2005, there were five species of Herba Epimedii:
Epimedium brevicornum Maxim., Epimedium sagittatum
(Sieb.et Zucc.) Maxim., Epimedium pubescens Maxim., Epi-
medium wushanense T.S. Ying, and Epimedium koreanum
Nakai [11]. Icariin was the index component for the quality
control of the antiosteoporotic herbal Fufang [11]. Since the
2010 Chinese Pharmacopoeia, E. wushanense T.S. Ying has
been separated as a new TCM and epimedin-C has been
selected as the index component for its quality control [12].
Different species of Herba Epimedii have varying flavonoids
with different concentrations. Even the same species may
have different compositions if they are from different loca-
tions, e.g., E. sagittatum in the Guizhou province contains
more icariin and epimedin-C than that in Henan or Hubei
province [13]. It is mandatory to specify the species and lo-
cations of herbs for making herbal Fufang in TCM. XLGB
contains E. pubescens from the Sichuan province in its
formulation, where its index component icariin has at least
1.4% of the total flavonoids for quality control [13]. With the
increasing demand for XLGB as preventive herbal Fufang
against osteoporosis in an aging society in China, it is indis-
pensable to seek other species of Herba Epimedii for
formulatingXLGBherbalmedicine for clinical applications. E.
koreanum in the Chinese Pharmacopoeia became a potential
candidate with following three distinguished advantages: (1)
large resources available in Liaoning province [12]; (2) almost
all of the flavonoids are found in E. pubescens although the
content of each flavonoid may vary [13]; and (3) the content
of icariin, the index component inXLGB for its quality control,
in E. koreanum is found more than that in E. pubescens from
Sichuan used for formulating commercial XLGB [13].
In order to evaluate the potential of E. koreanum from
Liaoning for potential replacement of E. pubescens from
Sichuan used for formulating XLGB Fufang, we prepared
XLGB particles containing E. koreanum (XEK) using the same
manufacturing process as the commercial ones made of E.
pubescens (XEP). Ultra performance liquid chromatography
(UPLC) was used to demonstrate the different chemical
constitutes in XEK and XEP; and then those compounds with
different contents were tested for their bioactivity in vitro.
16 S.-H. Chen et al.Lastly, an in vivo experimental efficacy study was designed
based on a null-hypothesis, i.e., to prove or disprove the
similarity in the treatment efficacy of XEP and XEK. State-
of-the-art imaging techniques, biomechanical tests, histo-
logical, and cytological evaluation were adopted to char-
acterise and compare the BMD, bone strength, and
microstructure of bone tissue between the two treatment
groups using an established OVX rat model [9,14].
Materials and methods
Materials
Two kinds of XLGB particles formulated with either of the
two species of Epimedium were provided by Guizhou
Tongjitang Pharmaceutical Co., Ltd. (Lot no. of XEP:
110618). Chromatography grade acetonitrile and water
were purchased from Fisher Scientific (Fair Lawn, NJ, USA).
Acetic acid was obtained from Sigma-Aldrich (St. Louis,
USA). All reference standards were isolated from commer-
cial available XLGB extracts by various columns chroma-
tography and were unambiguously identified by hygrogen-1,
carbon-13 nuclear magnetic resonance technique. Cell
culture reagents were obtained from Gibco (USA). Cell
Counting Kit-8 (CCK-8) was purchased from DOJINDO Lab
(Tokyo, Japan). Alkaline phosphatase kit (COD 11592) was
obtained from Biosystems (Spain).
UPLC chromatographic conditions for XLGB
XLGB with a weight of 5 g was extracted with 70% methanol
with 50 mL [13]. Firstly, ultrasound was performed twice
that lasted for 30 minutes each time when 70% methanol
was supplemented to the original volume. Thus, the final
concentration was 100 mg/mL for both XEP and XEK.
UPLC analyses were performed using a Thermo UPLC
UltiMate 3000 system (Thermo Fisher Scientific, USA)
equipped with a binary solvent system, an automatic sam-
ple manger and photodiode array detector [15]. The chro-
matographic separation was carried out on an Acquity UPLC
BEH C18 column (2.1 mm  5 mm, 1.7 mm) (Waters, USA) at
a temperature of 30C. The mobile phase consisted of
eluent A (0.1% acetic acid in water, v/v) and eluent B (0.1%
acetic acid in acetonitrile, v/v) was delivered at a flow rate
of 0.4 mL/min by using a liner gradient program as follow:
2e30% B from 0 minutes to 20 minutes, 30e48% B from 20
minutes to 30 minutes, 48e80% B from 30 minutes to 32.5
minutes, 80e100% B from 32.5 minutes to 35 minutes. After
holding 100% B for the following 5 minutes, the column was
returned to its starting condition. Detection wavelength
was at 270 nm in the ultra-violet detector. The chromato-
graphic peaks were identified by comparing their retention
time with that of each reference compound, which was
eluted in parallel with a series of mobile phases [15].
In vitro bioactivity assay of six compounds
The six compounds were identified and named by C1:
hexandraside F, C2: epimedin A, C3: epimedin B, C4: epi-
medin C, C5: icariin, and C6: 200-O-rhamnosylicariside II. Ratosteogenic UMR 106 cells were used for proliferation,
alkaline phosphatase (ALP) activity, and receptor activator
of nuclear factor-kappaB ligand/osteoprotegerin (RANKL/
OPG) assay.
UMR 106 osteoblastic cells were purchased from Amer-
ican Type Culture Collection, Manassas, VA, USA. They were
maintained in Dulbecco’s modified Eagle’s medium with
10% foetal bovine serum in an incubator with 5% CO2 at
37C. MTT, ALP activity, and real-time polymerase chain
reaction were tested according to our previously published
protocol [16]. Quantitative real-time polymerase chain re-
action was performed using the following primer sets:
RANKL-R-T forward, 50-CATCGGGTTCCCATAAAGTC-30;
RANKL-R-T reverse, 50-CTGAAGCAAATGTTGGCGTA-30; OPG-
R-T forward, 50-CACCATGTACCGATTGTATC-30; OPG-R-T
reverse, 50-AGCCCAGTGACCATTCCTAA-30; GAPDH-R-T for-
ward, 50-CAAGTTCAACGGCACAGTCA-30; GAPDH-R-T
reverse, 50-CCATTTGATGTTAGCGGGAT-30.
Experimental animals and study design
The Animal Experimental Ethics Committee of the principal
investigator’s institution approved the study protocol
(Ref. no: 11/065/MIS-5). Thirty-two adult female Sprague-
Dawley rats (12-weekoldwith bodyweight of 220 20 g)were
obtained from the Laboratory Animal Services Centre of the
Chinese University of Hong Kong. All animals were allowed to
acclimate in a temperature-controlled room (25 2C) under
a 12-hour reversed light-dark schedule. The rats were used
either as sham-operated (sham, n Z 8) or ovariectomised
groups (OVX, n Z 24). Sham-operated rats were only sub-
jected to laparotomy under general anaesthesia by intra-
peritoneal injection (0.2 mL/100 g body weight) of ketamine
combined with xylazine, while other rats were anaesthetised
for performing OVX. Upon recovery from operation, animals
were body-weight-matched and randomly assigned into the
following four experimental groups: Sham group; OVX group;
OVXþ XEK (XEKgroup); andOVXþ XEP (XEPgroup). According
to the clinically effective dosage of XLGB, the conversed and
equivalent effective dosage from human to rats with XLGB
powder was 225 mg/kg/day [17]. Herbal Fufang particles
dissolved in the distilled water were all administrated orally
through a custom-made stomach tube, which started onDay 4
after OVX for 12 weeks. Sham and OVX groups were given
normal saline throughout the experimental period.
After treatment, rats were given subcutaneous injection
of calcein green (5 mg/kg) and xylenol orange (90 mg/kg) in
a time sequence of 10 days and 3 days before euthanasia for
studying bone mineral apposition [14]. Before euthanasia,
blood was collected via cardiac puncture for serum isola-
tion that were then stored at 80C before the biomarkers
assay. The left tibiae and the fourth lumber vertebrae were
dissected for measurement of trabecular microarchitecture
followed by three-point bending test for the tibia and
compressive strength test for the vertebra.
Micro-computerised tomography
The fourth lumbar (L4) vertebra and the proximal tibia
were scanned by micro-CT system (mCT-40, Scanco Medical,
Bru¨ttisellen, Switzerland) using our established protocol
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lumbar vertebra or for 5 mm from top of tibia to distal di-
rection of tibia in a spatial resolution of 17 mm per voxel
with a 1024  1024 image matrix. For separating the signals
of the mineralised tissue from the background signal,
background noise was removed using a low-pass Gaussian
filter (Sigma Z 1.2, Support Z 2) with mineralised tissue
being defined at a threshold of 220. Three-dimensional
structures of trabecular bone were then reconstructed.
BMD, bone tissue volume fraction (BV/TV), connective
density, trabecular number (Tb.N), trabecular thickness
(Tb.Th), and trabecular separation (Tb.Sp) were measured
separately using built-in software [14,19].
Mechanical testing
A material test machine (H25KS; Hounsfield Test Equipment
Ltd. UK) with a 250 N load cell was used for the biome-
chanical tests. An axial compression test was performed to
analyse the mechanical strength of the lumbar vertebra
(L4) [20]. For the compression test, planoparallel surfaces
were obtained by removing the cranial and caudal ends of
the vertebral specimen. From the vertebral body, a central
cylinder with planoparallel ends and a height of approxi-
mately 5 mm was obtained. A craniocaudal compression
force was applied to the specimen using a steel disk at a
deformation rate of 2.5 mm/min. Compressive strength
(Mpa), E-modulus (Mpa), and energy at yield (J) parameters
were recorded for statistical analysis.
Three-point bending test was performed to analyse the
mechanical strength of tibia midshaft [21]. The left tibia
was positioned horizontally with the anterior surface up-
wards on a special holding device with supports located
with 12 mm apart. A displacement rate of 5 mm/min was
selected for applying the loading vertically to mid-diaphysis
on the anterior surface upward until a fracture occurred
using our established protocol [22]. Failure force (N) and
stiffness (N/mm) was recorded for statistical comparison.
Serum PINP, CTX, and E2 measurement
Bone formation marker, including amino-terminal propep-
tide of type I collagen (PINP) and bone resorption marker,
carboxy-terminal telopeptide (CTX), as well as estradiol
(E2), were assayed using enzyme-linked immunosorbent
assay (ELISA) kits (IDS Ltd., Boldon, UK) [23]. Six calibrators
at different PINP, CTX, or E2 concentrations supplied by the
company were measured for the standard curve.
Bone histomorphometric analysis
Sequential fluorescence labelling was used to study bone
dynamic bone remodelling within the trabecular bone of
proximal tibiae using our established protocol [23,24].
Samples were fixed in 10% neutral buffered formaldehyde
for 3 days. The fixed samples were then dehydrated,
cleared and embedded in methyl methacrylate (MMA,
Mecck-Schuchardt, Germany). After hardening, midcoronal
sections for trabecular bone were prepared for proximal
tibiae at a thickness of 5 mm (LEICA SM2500E, Leica In-
struments, Nussloch, Germany). The trabecular sectionswith Goldner’s Trichrome staining were used for histologi-
cal and cytological evaluation, and the fluorescence images
were taken and evaluated as well using professional imag-
ing and bone histomorphometry software (Osteometrics,
Atlanta, GA, USA) under fluorescence microscope (Leica
image analysis system, DM5500, Germany) [23,25]. The
region of 1.67 mm  1.10 mm in trabecular bone below
growth plate was defined for quantification. Bone histo-
morphometric parameters were calculated and expressed
by the ratio of osteoblasts surface and bone surface (Ob.S/
BS), the ratio of erosion surface and bone surface (ES/BS),
the ratio of osteoid surface and bone surface (Os.S/BS), fat
cells area (Fc.Ar), osteoid area (Os.Ar), mineralizing sur-
face (MS), mineral apposition rate (MAR), bone formation
rate per unit of bone surface (BFR/BS), and bone formation
rate per unit of bone volume (BFR/BV) according to the
published guideline for bone histomorphometry [26].
Statistical analysis
All quantitative data were presented as mean  standard
deviation. Differences in bone density and micro-
architecture, bone mechanical properties, bone turnover
biochemical markers, histomorphometry, as well as the
in vitro evaluations were compared using one-way analysis
of variance with Bonferroni post hoc test to determine
group differences using SPSS statistical software (SPSS
version 17.0, Chicago, IL, USA). Statistical significance was
set at * p < 0.05, **p < 0.01, or ***p < 0.001.
Results
Similarity and differences of chemical compounds
in XEK and XEP
Figure 1A showed the UPLC profiles of XEK and XEP.
Figure 1B, C, and D presented the enlargement of the profile
(Figure 1A) at 0e16 minutes, 16e31 minutes, and 31e37
minutes, respectively. The different chemicals between XEK
and XEP were mainly found on the peaks at 16e31 minutes
(Figure 1C). By comparing the retention time with the
reference standard isolated from XEP, six compounds (peaks
were indicated with the red 1e6 numbers in Figure 1E) were
identified as C1: hexandraside F, C2: epimedin A, C3: epi-
medin B, C4: epimedin C, C5: icariin and C6: 200-O-rhamno-
sylicariside II. There were higher content of C1, C2, C3, and
C5 in XEK and higher content of C4 and C6 in XEP. The peak at
19.18 minutes was speculated to be icaritin-3-O-a-L-rham-
noside, which was identified using high performance liquid
chromatography-mass spectrometry [27]. The retention
time, peak area, and the related peak area were listed in
Table 1, and the total relative peak areas of these seven
compounds are 22.57 and 22.19 in XEK and XEP, respectively.
In vitro bioassay of six identified compounds
Cell proliferation assay
For test cells proliferation, four concentrations of all six
compounds were used for assay, including 0.01mM, 0.1mM,
1mM, and 10mM. No significant difference was found
Figure 1 Ultra performance liquid chromatography profiles of different chemical constituents in Epimedium koreanum (XEK) and
Epimedium pubescens (XEP). (A) Ultra performance liquid chromatography profile of XEK and XEP; (B,C,D) enlargement of the
profile at 0e16 minutes, 16e31 minutes, and 31e37 minutes, respectively The differences between XEK and XEP mainly found on
the peaks (indicated with the red arrows) at 16e31 minutes; and (E) by comparing the retention time with the reference standard
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Table 1 Retention time, area, and relative area of the identified peaks in Epimedium pubescens and Epimedium koreanum.













1 Hexandraside F 16.677 11.1703 3.74 / / /
2 Epimedin A 17.033 4.5455 1.52 17.093 1.8292 0.56
3 Epimedin B 17.31 6.0568 2.03 17.353 2.1253 0.65
4 Epimedin C 17.64 7.1863 2.4 17.673 43.1011 13.24
5 Icariin 17.777 31.6835 10.6 17.817 10.5053 3.23
* Icaritin-3-O-a-L-rhamnoside 19.177 4.2537 1.42 19.243 0.5576 0.17
6 200-O-rhamnosylicariside II 24.7 2.5743 0.86 24.71 14.1174 4.34
Total rel. area N.a. 22.57 N.a. 22.19
Rel. area Z relative area; Ret. time Z retention time; N.a. Z Not applicable; XEK Z Epimedium koreanum; XEP Z Epimedium
pubescens.
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(p > 0.05). (Figure 2A).
ALP activity assay
The results showed the increased ALP activity in C4
(160.6%), C5 (141.5%), and C6 (169.3%) treatment groups in
the concentration of 0.1mM as compared with the control
group (100%) (p < 0.05 or p < 0.01) (Figure 2B).
Ratio of RANKL and OPG mRNA expression
The concentration of all compounds was selected as 0.1mM.
Compared with control group (100%), significantly
decreased RANKL/OPG level was found in C1 and C3
treatment groups that were C1 (77.2%) and C3 (81.8%)
(p < 0.05), while more significantly decreased RANKL/OPG
level was found in C4, C5, and C6 treatment groups that
were C4 (65.2%), C5 (53.5%), and C6 (61.7%) (p < 0.01 or
p < 0.001).
Body and uterus weight and E2 assay
Significantly increased body weight was found in the OVX
group and decreased uterus weight was found in the OVX
group, XEK group, and XEP group compared with that of the
sham group (p < 0.001, n Z 6), indicating that the OVX
operations was performed successfully in rats (Figure 3A).
Compared with the sham group, the significantly lower
serum E2 level in the OVX group was found and shown in
Figure 3A that indicated successful depletion of E2 in OVX
rats. E2 in both XEK and XEP groups were significant higher
than that in the OVX group (p < 0.05 for XEK and p < 0.01
for XEP).
Bone evaluation
The bone mass and bone microarchitecture of L4 vertebrae
(Figure 4A) and proximal tibiae (Figure 4B) were measured
and analysed using micro-CT. The results of Figure 4A
showed significantly lower relative bone volume and BMD inisolated from XEP, six compounds (peaks were indicated with the re
epimedin A, C3: epimedin B, C4: epimedin C, C5: icariin, and C6: 200
C3, and C5 in XEK and higher contents of C4 and C6 in XEP. The
rhamnoside, which was identified using high performance liquid chL4 vertebrae in OVX group (p < 0.01) compared with that of
sham group. As compared with OVX group, significantly
higher values (higher percentages) were shown both in XEK
and XEP groups: BV/TV (53.5% and 63.7%), BMD (mg HA/cm3)
(15.2% and 22.9%), Conn.D. (1/mm3) (17.9% and 40.9%),
Tb.N (1/mm) (11.5% and 25.4%), and Tb.Th (mm) (18.8% and
23.6%), respectively (p < 0.05 for all). There was no sig-
nificant difference in above parameters found between the
two treatment groups (p > 0.05). In Figure 4B, as compared
with the sham group, the significant lower values measured
at proximal tibiae in OVX group indicated OVX-induced
reduction in both bone mass and BMD (p < 0.01). In the
treatment groups, XEP group showed significant higher
values compared with the OVX group (p < 0.05), while XEK
group only showed marginal increase (p> 0.05). The results
presented the higher percentages than that in OVX group
that were BV/TV (29.2% vs. 53.6%), BMD (mg HA/ccm)
(18.9% vs. 25.3%), Conn.D. (1/mm3) (54.9% vs. 96.3%), Tb.N
(1/mm) (29.9% vs. 46.3%), and Tb.Th (mm) (30.9% vs.
30.8%), respectively (Figure 4B). However, there was no
difference found between the XEP group and XEK group
(p > 0.05).Bone mechanical properties
Figure 3C and D present the mechanical properties of L4
vertebra and the tibia midshaft. Compression test on L4
vertebra (Figure 3C) showed that compared with the
significantly lower values in OVX group, the values in XEK
and XEP groups were all significantly higher in E-modulus
(Mpa) (81.8% and 72.1%), compressive strength (Mpa)
(74.6% and 87.3%), and energy (J) (123% and 199%),
respectively (p < 0.05 for all). However, the three-point
bending test on tibiae (Figure 3D) showed no significant
differences in the tested mechanical parameters be-
tween OVX group and XEK or XEP groups (p > 0.05 for
both).d 1e6 numbers in E) were identified as C1: hexandraside F, C2:
-O-rhamnosylicariside II. There were higher contents of C1, C2,
peak at 19.18 minutes was speculated to be icaritin-3-O-a-L-
romatographyemass spectrometry.
Figure 2 In vitro evaluation of six identified compounds. (A) Cell proliferation assay: for test cells proliferation, four concen-
trations of all six compounds were used for assay, including 0.01mM, 0.1mM, 1mM, and 10mM. No significant difference was found
between the treatment group and the control group at three different concentrations (p > 0.05, nZ 3); (B) alkaline phosphatase
assay activity assay: the results presented the increased alkaline phosphatase activity in C4, C5, and C6 treatment groups in the
concentration of 0.1mM in contrast with the control group (*p < 0.05, **p < 0.01, n Z 3); (C) the ratio of receptor activator of
nuclear factor kappa-B and osteoprotegerin mRNA expression: The results showed significantly decreased receptor activator of
nuclear factor kappa-B/osteoprotegerin level in compounds treatment groups that C1, C3, C4, C5, and C6 (*p < 0.05, **p < 0.01,
***p < 0.001, n Z 3). ALP Z alkaline phosphatase; C1 Z hexandraside F; C2 Z epimedin A; C3 Z epimedin B; C4 Z epimedin C;
C5 Z icariin; C6 Z 200-O-rhamnosylicariside II; Cntrl Z control; RANKL/OPG Z receptor activator of nuclear factor kappa-B/
osteoprotegerin.
20 S.-H. Chen et al.Bone turnover markers assay
Compared with the sham group, significantly higher levels
of serum PINP and CTX were found in the OVX group
(Figure 3B), indicating increased bone turnover in OVX rats.
There was no significant difference found between OVX
group and XEK group or XEP group in PINP (p > 0.05 for
both), while CTX was found significantly lower only in the
XEP group but not in the XEK group compared with the OVX
group (p < 0.05).
Bone histomorphometry
In histological evaluation, Goldner’s trichrome staining and
fluorescent images of MMA sections for trabecular bone
presented the cytological significant difference between
the OVX group and XEK group or XEP group (Figures 5 and 6).
The OVX group showed significantly lower values than the
sham group. As compared with the OVX group, a signifi-
cantly higher percentage of values were found in the XEK
group and XEP group respectively, including Ob.S/BS (91.5%
and 121.9%), Os.S/BS (125.4% and 131.8%), Os.Ar (271.9%
and 349.7%), MS (49.7% and 73.4%), and MAR (113.7% and
134.2%), while significantly lower levels in Fc.Ar (37.2% and
49.2%), ES/BS (23.6% and 29.9%), BFR/BS (35.2% and 31.9%),
and BFR/BV (61.2% and 63.1%) (p < 0.05 for all). The resultsindicated the dual functions of XLGB Fufang with both bone
anabolism enhancement and bone erosion inhibition for
two different species of Epimedium in terms of the
enhanced osteoblastic activities and inhibition of osteo-
clastic function.
Discussion
Our chemical analysis demonstrated that the content of
icariin in XEK, an index for the quality control of XLGB
Fufang, is comparable to XEP that also met the regular
requirements in the Chinese Pharmacopoeia, in spite of
some degree differences in several flavonoid contents be-
tween XEK and XEP [11,13]. The general objective of our
comparable study was however designed to prove if XEK
was able to substitute XEP in traditional XLGB formula with
regards to its treatment efficacy, including mechanical
properties and histomorphometry [28] in addition to their
associated biological and biochemical mechanisms using
both in vitro and ex vivo assays.
Micro-CT analysis demonstrated the efficiency in the
prevention of OVX-induced bone loss at fourth lumbar
vertebrae and proximal tibiae in both the XEK group and
XEP group as compared with the OVX group. Clinical rele-
vant characterisation of aging skeleton is the loss of a
substantial fraction of its mechanical competence,
Figure 3 Quantitative analysis of anthropometric, biochemical and biomechanical tests. (A) Body and uterus weight and
estradiol (E2) assay: significantly increased body weight and decreased uterus weight of rats were found in ovariectomised (OVX),
Epimedium koreanum (XEK), and Epimedium pubescens (XEP) groups compared with that in sham group (***p < 0.001, nZ 6); and
compared with the sham group, significantly lower levels of serum E2 were found in OVX group. E2 in both XEK and XEP groups were
significantly higher than that in the OVX group (*p < 0.05 for XEK and **p < 0.01 for XEP, nZ 4). (B) Enzyme-linked immunosorbent
assays of biochemical markers in serum. Compared with the sham group, significantly higher levels of serum amino-terminal
propeptide and carboxy-terminal telopeptide were found in OVX group, yet without significant difference among OVX group and
XEK or XEP groups in amino-terminal propeptide (p > 0.05, nZ 8), while carboxy-terminal telopeptide was found to be significantly
lower in XEP group compared with OVX group (*p < 0.05, n Z 8). (C) Compression test on lumbar vertebra showed no significant
difference between the XEK group and XEP group, but all showed significantly higher E-modulus, compressive strength, and energy
as compared with that of OVX group (*p < 0.05, **p < 0.01, n Z 6). (D) Three-point bending test on the midshaft of the tibiae
showed no significant difference in maximum force, energy, and stiffness among OVX and the two treatment groups (p > 0.05,
n Z 6). CTX Z carboxy-terminal telopeptide; E2 Z estradiol; PINP Z amino-terminal propeptide.
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compartments. Compression test of the current study on
trabecular bone of fourth lumbar vertebrae presented the
remarkable higher bone strength properties in both the XEKgroup and XEP group as compared with the OVX group.
However, the tibiae cortical bone in the OVX group did not
show significant lower bone strength than that in the sham
group, and that also did not present significant better
Figure 4 (A) Representative micro-computed tomography two-dimensional and three-dimensional images and quantitative analysis of the fourth lumbar vertebrae (L4) 3 months
after treatment showed no differences between Epimedium koreanum (XEK) and Epimedium pubescens (XEP) groups, and both with significantly higher bone tissue volume
fraction, bone mineral density, connective density, trabecular number and trabecular thickness, but lower trabecular separation as compared with that of the ovariectomised
(OVX) group (*p < 0.05, n Z 8). (B) Representative micro-computed tomography two-dimensional and three-dimensional images and quantitative analysis of proximal tibiae 3
months after treatment revealed no difference between the XEK group and XEP group. XEP showed significantly higher bone tissue volume fraction, bone mineral density,
connective density, trabecular number, and trabecular thickness, and lower trabecular separation as compared with the OVX group (*p < 0.05, n Z 8), and XEK showed
significantly higher trabecular thickness and lower Tb.Sp compared with the OVX group (p > 0.05, n Z 8). BMD Z bone mineral density; BV/TV Z bone tissue volume fraction;
Conn.d.Z connective density; OVXZ ovariectomised; Tb.N.Z trabecular number; Tb.SpZ trabecular separation; Tb.ThZ trabecular thickness; XEKZ Epimedium koreanum;












Figure 5 Representative Goldner’s trichrome staining and histomorphometry in undecalcified MMA sections. Significantly higher
osteoblasts surface and bone surface, osteoid surface and bone surface, and osteoid area, and significantly lower fat cells area and
erosion surface and bone surface were found in Epimedium koreanum and Epimedium pubescens groups as compared with the
ovariectomised group (*p < 0.05 or **p < 0.001, n Z 6), yet without difference found between Epimedium koreanum group and
Epimedium pubescens group. ES/BSZ erosion surface and bone surface; Fc.ArZ fat cells area; Ob.S/BSZ osteoblasts surface and
bone surface; Ob.S/BS Z osteoid surface and bone surface; Os.Ar Z osteoid area; OVX Z ovariectomised; XEK Z Epimedium
koreanum; XEP Z Epimedium pubescens.
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with OVX group. This result implied the tibiae cortical bone
was not remarkably impaired by OVX itself or at least in
early stage of oestrogen depletion designed for the current
study. The fact that most osteoporotic fractures occur at
locations rich in trabecular bone, that explained the lower
trabecular bone strength in vertebral bone and/or early
sensitive changes of trabecular bone in bone strength, than
that of the cortical bone dominant tibial shaft where it
showed slow and less sensitive changes in bone strength
[29,30]. In the present study, we did not find differences in
structural and mechanical differences between the XEK
group and XEP group, implying similar antiosteoporotic ef-
ficacy of two different species of Epimedium. The in vitro
results in Figure 2 showed higher ALP activity (Figure 2B)
and lower RANKL/OPG ratio (Figure 2C), especially in the
three kinds of compounds e epimedin C, icariin, and 200-O-
rhamnosylicariside II. The inverted relationship found be-
tween ALP activity and RANKL/OPG ratio suggested the
osteogenic and antiosteoclastic potentials in the two
treatment groups due to multiple herbal compounds [31]. It
is known that higher ALP activity indicates upregulated
osteogenesis, and higher RANKL/OPG ratio secreted from
osteoblasts implies inhibition to osteoclast maturation and
function, i.e., less activated osteoclasts and weaker bone
resorption activity. This was supported by histomorpho-
metric data in Figure 5 where the lower ES/BS ratio was
measured in the two treatment groups as compared with
the OVX group. For the comparative analysis between the
two Epimedium species, higher levels of icariin in the XEK
group, and also higher levels of epimedin-C and 200-O-
rhamnosylicariside II in the XEP group could present a slight
difference and similar osteogenesis abilities that result inultimately similar effects of bone mass, bone microstruc-
ture, and biomechanical properties.
For investigationof further underlyingmechanismsof XLGB
formulae on the prevention of oestrogen-depletion induced
bone loss, histomorphometry was performed for quantitative
comparison. The results showed higher bone turnover (high
ES/BS in Figure 5 and high BFR/BS and BFR/BV in Figure 6) in
the OVX group as compared with that of the sham group.
Postmenopausal osteoporosis is a bone disease in which the
bone resorption rate is increased because of oestrogen defi-
ciency, and BFR/BS or BFR/BV is also increased to compensate
for the high bone resorption. The common form of high turn-
over (high BFR/BS and BFR/BV) is deleterious to the skeleton
because there is net loss of bone. Especially in the early
stages, the tested bone turnover dynamic parameters are al-
ways higher, such as MS/BS, MAR, BFR/BS, and BFR/BV in
histomorphometry. This could beconsistentwith thebalanced
and coupled bone formation and resorption that did not result
in detectable changes in bone volume. However, for the
relative late stage of osteoporosis, such asmore than3months
post-OVX in our current experimental study, the bone forma-
tion ratewas decreased so that it seemed contradictory to the
finding on the resorption rate and the net bone loss. Su et al
[32] reported a decreased MAR and BFR/BS 35 days post-OVX
operation in mice models compared with that 14 days post-
OVX operation. In the presented study (Figure 6), although a
lowerMARwas observed in theOVXgroup that used to standby
the less new bone formation, the higher BFR/BS and BFR/BV
were still found in the OVX group compared with the sham
group that was supported by higher MS/BS, i.e., with more
mineralising surface. Theeffective treatment in theXEKgroup
or XEP group could supplement the deficiency of bone for-
mation in OVX rats via overall enhanced osteogenic activity.
Figure 6 Representative fluorescence imaging and histomorphometry in undecalcified MMA sections. (A) Distance between the
two-labelled lines in fluorescence images for calculating bone mineral apposition rate (MAR), and superimposed fluorescence and
optical view in trabecular bone site of proximal tibiae among different groups. The MAR in ovariectomised (OVX) group was
significantly reduced as compared with that of Sham group. However, the distance in Epimedium koreanum (XEK) and Epimedium
pubescens (XEP) groups showed significantly larger width in contrast to OVX group (*p < 0.05 or **p < 0.001, nZ 6). (B) Mineralised
matrix properties between OVX and two treatment groups. No difference was found between XEK and XEP groups, but significantly
higher levels of mineralising surface and MAR were found in both XEK and XEP groups as compared with that of OVX group, while
lower levels of bone formation rate per unit of bone surface and bone formation rate per unit of bone volume were found in both
XEK and XEP groups in contrast to OVX group (*p < 0.05 or **p < 0.001, n Z 6). BFR/BS Z bone formation rate per unit of bone
surface; BFR/BV Z bone formation rate per unit of bone volume; MAR Z bone mineral apposition rate; OVX Z ovariectomised;
XEK Z Epimedium koreanum; XEP Z Epimedium pubescens.
24 S.-H. Chen et al.Our previous studies showed that Epimedium-derived flavo-
noids, especially flavonoid aglycone icaritin, possess great
potential in increasing osteoblast-like cell proliferation,
osteoid formation, and mineralisation [33,34]. As compared
with theOVX group, the treatment groups of our current study
showed less adipogenesis and more osteoid formation adja-
cent to the mineralised bone with even enhanced osteoblasts
and suppressed osteoclasts activities based on the results of
Goldner’s Trichrome staining. It implied that herbal Fufang
XLGBwas formulated with the key composition of Epimedium
that showed inherent osteogenic activity in terms of promot-
ing osteoid formation and mineralisation, as well as inhibitory
effects in the suppression of osteoclasts activity as evidenced
with reduced bone erosion surface. Epimedium-derived
flavonoid icaritin alone could enhance bone mesenchymal
stem cell (MSC) homing and differentiation in vitro, which
might be directly involved in the bonemorphogenetic proteinsignalling pathway and associated with the Wnt signalling
pathway [33,34]. In addition, the role of adipogenic reduction
could be another regulation of pathologicmechanisms. During
osteoporosis development, the enhanced differentiation of
adipocytes from bone MSCs inhibit the osteoblast differenti-
ation. Icaritin has effects on the inhibition of adipogenic dif-
ferentiation of MSCs [34]. As one of the bioactivemolecules of
Epimedium, icaritin or desmethylicaritin may present similar
mechanisms or signalling pathways in osteogenesis and adi-
pogenesis with XEK and XEP. The exact difference in mecha-
nism or signalling pathway between the two species of
Epimedium could not be delineated in the current study, and
therefore we used bone structure and mechanical properties
as the end-point of intervention effects.
As expected, the serum E2 significantly decreased in the
OVX rats as compared with that of the sham group. Mean-
while, serum E2 in the XEP group and XEK group were both
Different Epimedium for osteoporosis prevention 25significantly higher than that in the OVX animals. ELISA was
used for the current study, which is a test that uses anti-
bodies and colour change to identify a substance. ELISA for
testing E2 uses an E2 antibody as the solid-phase in this
enzyme immunoassay to detect the presence of E2 in the
serum due to its affinity to the E2 antibody. In this immu-
noassay, other substance such as the phytoestrogens or
their metabolites of XLGB in serum, which are able to bind
to the E2antibody, would also be tested as E2. Previous
studies found that serum E2 levels were much higher when
measured by immunoassay compared with that determined
by mass spectrometry in patients treated with exemestane,
which is steroidal with a similar structure with E2 [35,36].
Furthermore, it was reported that some compounds in XLGB
were able to bind to ER [37], so we postulated that the
higher “E2 level” in XLGB groups was not the real serum E2.
This was further indicated by the results that E2 was able to
significantly increase the uterus weight in OVX animals as
reported before. Unlike E2, XEP or XEK was a
phytoestrogen-rich formula that did not exert similar
stimulating effect on uterus. This also hinted that MS would
be more favourable to test serum E2 when treated with
oestradiols or phytoestrogens. It is known that oestrogen
expresses its activities by binding to different oestrogen
receptors (ERs), including ERa and ERb. ERb is more abun-
dant than ERa in bone tissue, while ERa it is mainly
distributed in reproductive cells and is the dominant re-
ceptor mediating the effects of E2 in the breast and uterus
[25,38]. Therefore, it is postulated that XEP or XEK may
have potential antiosteoporotic effects on OVX mice via
ERb in bone or membrane/cytoplasm-initiated oestrogen
receptor signalling pathway.
The biochemical markers served as an important
modulator of bone turnover always indicate excessive
resorption by osteoclasts or inadequate bone formation by
osteoblasts due to the depletion of oestrogen in women
[29]. An increase of bone turnover has been documented at
the time of menopause that is 37e52% and 79e97% in-
creases in the bone formation and bone resorption marker
levels, respectively, and this high bone turnover is just
associated with a low bone mass. PINP and CTX are relevant
bone formation and resorption markers that reflect and
determine biological response of skeleton tissues during
drug treatment for osteoporosis. Based on the results,
there were significantly higher levels of PINP and CTX in
OVX group than that in sham group. As compared with the
OVX group, no significantly higher PINP level detected both
in XEK and XEP groups, which could be explained as that a
short detectable time window used to reflect the actual
levels of serum biomarkers that should be followed by a
stable platform of bone formation during osteoporosis
treatment. In addition, significantly higher CTX level was
found in OVX group compared with the sham group that
implied a high bone turnover activity. Our in vitro tests
showed a significant decrease in RNAKL/OPG level in epi-
medin C, icariin, and 200-O-rhamnosylicariside II com-
pounds, so both XEK and XEP should play an antiresorption
role as supported by significantly lower serum CTX level in
XEP group and less prominently lower CTX in XEK group
compared with the OVX group, an index of suppression of
osteoclastic activities during bone remodelling. However,
there was no significantly decreased CTX level found in XEKgroup in contrast to OVX group, and this might be explained
by a mechanism of ‘uncoupling’ that the deterioration of
microstructure often requires a longer period of time, and
the alterations of biochemical markers on bone turnover in
serum become detectable shortly after pharmacological
intervention in osteoporosis therapy [39]. It might still have
certain differences between XEK and XEP in terms of
effective time window although at the time of study
completion it did not show significant difference in CTX
level between XEP and XEK groups. As the current study just
used one time point, i.e., end-point to measure the treat-
ment efficacy of XEK and XEP to osteoporosis, future
studies should be designed to detect temporal changes of
serum biomarkers.
The above results indicated treatment efficacy of herbal
Fufang XLGB containing either XEK or XEP for the preven-
tion of OVX-induced bone loss and deterioration of its me-
chanical properties. No significant difference was found
between the XEK group and XEP group, yet with the XEP
group showing slightly higher mean values, implying XEP
used for formulating herbal Fufang XLGB might even
possess better potentials for prevention of OVX-induced
bone loss. Based on the chemical analysis of XEP and XEK,
seven flavonoids have different contents in two formulae.
There is more epimedin C and 200-O-rhamnosylicariside II in
XPE than that in XEK, and more hexandraside F, epimedin A,
epimedin B, icariin, and icaritin-3-O-a-L-rhamnoside in XEK
than that in XEP. Our in vitro evaluation showed that epi-
medin A, epimedin C, icariin, and 200-O-rhamnosylicariside II
significantly promoted ALP activity in osteoblast-like cells,
while hexandraside F, epimedin B, epimedin C, icariin, and
200-O-rhamnosylicariside II all decreased RANKL/OPG, indi-
cating that they was able to inhibit osteoclastgenesis at a
10mM concentration. The in vitro results suggested that all
of the six compounds might contribute to the anti-
osteoporotic effects of two XLGB formulae and resulting in
the comparable efficacy of XEP and XEK. As the efficacy
evaluation was based on systemic biological effects, multi-
functional composite of herbal Fufang XLGB could facilitate
comprehensive effects in antiosteoporosis based on total
composed compounds. In addition, the chemical analysis
results are in line with our previous published report that
epimedin C is the main compound of E. pubescens, while
icariin is the main flavonoid in E. koreanum. As the main
components in XEP and XEK, respectively, the similar
bioactivity of epimedin C and icariin may contribute greatly
to prevention of OVX-induced bone loss with comparable
effects from different XLGB formulae. Various studies were
performed to investigate the efficacy [31], pharmacoki-
netics [40], and metabolism [41] of icariin. Recently, epi-
medin C had received more and more attention [42]. Both
epimedin C [42] and icariin [31] exerted antiosteoporosis
effects in OVX rats or mice. Further, our recent metabolic
study of XEP found that both epimedin C and icariin were
able to be absorbed into blood, moreover there was more
icariin in the plasma than epimedin C in the metabolites
although it was not the case in the original XEP herb [15].
Moreover, only the absorbed chemical components or the
related metabolites in blood, which maintained a certain
concentration in the target organ(s) for a period of time,
such as for the early time period, are essential to realize
their therapeutic effects. Thus, we should not only
26 S.-H. Chen et al.compare the chemical constituents of compounds in the
XLGB formula, but also investigate the metabolic profiles of
XEP and XEK in the future.
As a candidate for the selection of effective ingredient
to formulate antiosteoporosis herbal Fufang, the anti-
osteoporosis effect of E. koreanum could be further
investigated for exploring its dosing effects in the future
that should supplement low or high dosage groups of XEK
and XEP to investigate the optimal dose-effect dependent
manner for further reference to formulae selection and
evaluation.Conclusion
The formulation of commercially available antiosteoporosis
XLGB Fufang with either XEK or XEP showed similar efficacy
in the prevention and treatment of OVX-induced osteopo-
rosis, as measured for both bone mass and bone strength.
These findings implied that both XEK and XEP Epimedium
species could be potentially developed for formulation of
current herbal Fufang XLGB capsules for established clinical
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